MedTrace Logo

CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia

NCT05596266 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-10-27

No results posted yet for this study

Summary

This is a phase I, interventional, single arm, open label, clinical study to evaluate the safety and tolerability of CD5 CAR-T cells in refractory/relapsed CD5+ T-ALL patients who have no available curative treatment options.

Conditions

  • T-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

CD5 CAR-T

CD5 CAR-T will be administered by I.V. infusion.

Sponsors & Collaborators

  • Baoding Children's Hospital

    collaborator OTHER

  • Xuanwu Hospital, Beijing

    lead OTHER

Principal Investigators

  • Zhiguo Chen, PhD · Xuanwu Hospital, Beijing

  • Huyong Zheng, MD, PhD · Baoding Children's Hospital; Beijing Children's Hospital, Capital Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-25
Primary Completion
2024-12-31
Completion
2025-10-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05596266 on ClinicalTrials.gov